0001209191-23-058481.txt : 20231213 0001209191-23-058481.hdr.sgml : 20231213 20231213162544 ACCESSION NUMBER: 0001209191-23-058481 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231010 FILED AS OF DATE: 20231213 DATE AS OF CHANGE: 20231213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bozilenko Marina CENTRAL INDEX KEY: 0001853794 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35068 FILM NUMBER: 231484303 MAIL ADDRESS: STREET 1: C/O ACELRX PHARMACEUTICALS, INC. STREET 2: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACELRX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001427925 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1850 GATEWAY DRIVE STREET 2: SUITE 175 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: 650-216-3500 MAIL ADDRESS: STREET 1: 1850 GATEWAY DRIVE STREET 2: SUITE 175 CITY: SAN MATEO STATE: CA ZIP: 94404 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-10 0 0001427925 ACELRX PHARMACEUTICALS INC ACRX 0001853794 Bozilenko Marina C/O ACELRX PHARMACEUTICALS, INC. 1850 GATEWAY DRIVE, SUITE 175 SAN MATEO CA 94404 1 0 0 0 0 Common Stock 2023-10-10 4 A 0 581 0.00 A 2606 D Stock Option (Right to Buy) 0.684 2023-10-10 4 A 0 3487 0.00 A 2024-10-10 2033-10-10 Common Stock 3487 3487 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Effective on October 25, 2022, the issuer effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. /s/ Martha Adler, Attorney-In-Fact 2023-12-13